- An experimental Ebola vaccine from GlaxoSmithKline (NYSE:GSK) produced an immune response in all 20 healthy volunteers who received it, and did not cause any serious side effects, Reuters reports quoting the New England Journal of Medicine.
- The early-stage clinical trial, which began on Sept. 2, is primarily aimed at assessing how safe the vaccine is and will monitor the volunteers for 48 weeks.